{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:04:27Z","timestamp":1769695467738,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T00:00:00Z","timestamp":1598140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Background<\/jats:title><jats:sec><jats:label\/><jats:p>Japanese encephalitis virus (JEV) is endemic to tropical areas in Asia and the Western Pacific. It can cause fatal encephalitis, although most infected individuals are asymptomatic. JEV is mainly transmitted to humans through the bite of an infected mosquito, but can also be transmitted through blood transfusion. To manage the potential risk of transfusion transmission, pathogen inactivation (PI) technologies, such as THERAFLEX MB\u2010Plasma and THERAFLEX UV\u2010Platelets systems, have been developed. We examined the efficacy of these two PI systems to inactivate JEV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>Japanese encephalitis virus\u2013spiked plasma units were treated using the THERAFLEX MB\u2010Plasma system (visible light doses, 20, 40, 60, and 120 [standard] J\/cm2) in the presence of methylene blue at approximately 0.8\u2009\u03bcmol\/L and spiked platelet concentrates (PCs) were treated using the THERAFLEX UV\u2010Platelets system (UVC doses, 0.05, 0.10, 0.15, and 0.20 [standard] J\/cm2). Samples were taken before the first and after each illumination dose and tested for infectivity using an immunoplaque assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment of plasma with the THERAFLEX MB\u2010Plasma system resulted in an average of 6.59 log reduction in JEV infectivity at one\u2010sixth of the standard visible light dose (20\u2009J\/cm2). For PCs, treatment with the THERAFLEX UV\u2010Platelet system resulted in an average of 7.02 log reduction in JEV infectivity at the standard UVC dose (0.20\u2009J\/cm2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The THERAFLEX MB\u2010Plasma and THERAFLEX UV\u2010Platelets systems effectively inactivated JEV in plasma or PCs, and thus these PI technologies could be an effective option to reduce the risk of JEV transfusion transmission.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.16021","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T07:33:30Z","timestamp":1598254410000},"page":"2655-2660","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inactivation of <scp>Japanese<\/scp> encephalitis virus in plasma by methylene blue combined with visible light and in platelet concentrates by ultraviolet <scp>C<\/scp> light"],"prefix":"10.1111","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6385-1580","authenticated-orcid":false,"given":"Lina","family":"Rustanti","sequence":"first","affiliation":[{"name":"Research and Development Australian Red Cross Lifeblood  Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody","family":"Hobson\u2010Peters","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe M. G.","family":"Colmant","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy A.","family":"Hall","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[{"name":"Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Reichenberg","sequence":"additional","affiliation":[{"name":"Macopharma International GmbH  Langen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Tolksdorf","sequence":"additional","affiliation":[{"name":"Macopharma International GmbH  Langen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chryslain","family":"Sumian","sequence":"additional","affiliation":[{"name":"Macopharma  Tourcoing France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Gravemann","sequence":"additional","affiliation":[{"name":"German Red Cross Blood Service NSTOB  Springe Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-5097","authenticated-orcid":false,"given":"Axel","family":"Seltsam","sequence":"additional","affiliation":[{"name":"German Red Cross Blood Service NSTOB  Springe Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-6934","authenticated-orcid":false,"given":"Denese C.","family":"Marks","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Lifeblood  Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-8248","authenticated-orcid":false,"given":"Helen M.","family":"Faddy","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Lifeblood  Australia"},{"name":"School of Health and Sport Sciences University of the Sunshine Coast  Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,23]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8030111"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26902"},{"key":"e_1_2_9_4_1","unstructured":"World Health Organisation.Japanese Encephalitis 2019.https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/japanese\u2010encephalitis. Accessed November 12 2019."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2018.2291"},{"key":"e_1_2_9_6_1","unstructured":"Centers for Disease Control and Prevention.Japanese Encephalitis 2019.https:\/\/www.cdc.gov\/japaneseencephalitis\/. Accessed November 12 2019."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed4010038"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jme\/tjw165"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2401.171297"},{"key":"e_1_2_9_10_1","unstructured":"Australian Red Cross Blood Service.Guidelines for the Selection of Blood Donors. Melbourne: Australian Red Cross Blood Service;2018."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2016.01.005"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15332"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13519"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13729"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14256"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1011-1344(01)00206-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323786"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2012.01.008"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000441830"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-81-10-2471"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12888"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.16021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.16021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T17:53:20Z","timestamp":1693677200000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.16021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,23]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/trf.16021"],"URL":"https:\/\/doi.org\/10.1111\/trf.16021","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,23]]},"assertion":[{"value":"2020-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}